NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Nkarta, Inc. (NKTX) Stock Analysis

Nkarta, Inc. (NKTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NKTX

$2.92

+$0.13 (+4.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NKTX with… →

NKTX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.77
Previous Close
$2.79
Day's Range
2.75–2.93
52-Week Range
1.70–3.72
Volume
447.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.97
Valuation
Market Cap
$209.14M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.59
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$104.08M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
71.62M
1-Year Return
+37.09%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
664.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NKTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+57.84%
2025−25.70%
2024−62.27%
2023+10.18%
2022−60.98%
2021−75.03%
2020 (partial year)+28.33%

As of September 4, 2026.

NKTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$104.08M—
2024$0.00−$108.79M—
2023$0.00−$117.50M—
2022$0.00−$113.84M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$122.00M−$104.08M—
2024$0.00—−$128.19M−$108.79M—
2023$0.00—−$131.65M−$117.50M—
2022$0.00—−$118.96M−$113.84M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NKTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricNKTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Nkarta, Inc. (NKTX) is capitalised at $209.14M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 106.

The most recent close on file for NKTX is $2.92, dated September 4, 2026. That is +$0.13 (+4.66%) against the previous close. The 52-week range on file runs from $1.70 to $3.72. The latest close sits 71.76% above that 52-week low.

Financial Health

In fiscal 2025, Nkarta, Inc. reported revenue of $0.00. The same year closed with a net loss of $104.08M. Profit margin runs at 0%. Trailing earnings per share are −1.59.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.98. Daily returns over the trailing 6 years annualize to a volatility of 117%. The trailing one-year price return is +37.09%. Across 5 years the annualized return works out at −36.81%.

Growth & Income

No dividend is on file for NKTX.

2026 is still running; the price is +57.84% year to date. The strongest complete calendar year on file is 2023 at +10.18%; the weakest is 2021 at −75.03%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Nkarta, Inc. (NKTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nkarta, Inc. NKTX $209.14M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nkarta, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Visit website →